



RECEIVED

OCT 03 2002

1614/1

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$) 200

Complete if Known

Application Number 29/943,048
Filing Date Aug 30, 2001
First Named Inventor Dr. M. EL-Naggar
Examiner Name B. Kwon
Group Art Unit 1614
Attorney Docket No.

#3 RE

METHOD OF PAYMENT (check all that apply)

☐ Check ☒ Credit card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account: Visa / Exp. date 08/04

Deposit Account Number [Redacted]
Deposit Account Name Shaker Mousa / M. EL-Naggar

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments
☐ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	- Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims - 20** = X =
Independent Claims - 3** = X =
Multiple Dependent =

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 200

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	
		227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	200
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 200

SUBMITTED BY

Name (Print/Type) Mawahab EL-Naggar
Signature Mawahab EL-Naggar

Registration No. (Attorney/Agent)

Complete (if applicable)

Telephone 610-869-9358
Date 09/10/02

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
OCT 03 2002

TECH CENTER 1600/2900

Application of : El-Naggar et al. Examiner: B. Kwon
Appl. No. : 09/943,048 Art Unit: 1614
Filed : August 30, 2001
For : Treatment of Inflammatory, Cancer, and Thrombosis Disorders

#4
Abdman
NE

Commissioner of Patents
And Trademarks
Washington, D.C. 20231

Sir:

This Amendment responds to the Office Action mailed April 10, 2002. A request for two months extension of time accompanies this Amendment. Please amend the application as follows:

Response to Restriction Requirement

Applicants affirm, with traverse, election of group III (Claim 4) in response to a restriction requirement.

Amendment

IN THE CLAIMS:

Please amend claims 1 and 5 as follows:

1. (Amended) A method of treating inflammatory disorders in a mammal comprising administering to said mammal a combination of: (i) a standard therapeutic dose of a COX2 inhibitor selected from the group consisting of [(i)] celecoxib [(CelebrexR) [A,]] and rofecoxib [(VioxxR) [B], and other specific COX2 inhibitors [C]], (ii) low dose aspirin in the amount of [(C) 70-85 mg[(], and (iii) antioxidant flavanoids, flavonoids or isoflavones.
5. (Amended) The method of claim 1, wherein the [COX2 inhibitors is compound [A], compound [B] or compound [C] and] low dose aspirin [of 70-85 mg] is in an enteric coated formulation. [This preferred enteric-coated formulation should allow for improved efficacy and safety.]